

CITATION REPORT

List of articles citing

Imiquimod and resiquimod as novel immunomodulators

DOI: 10.1093/jac/48.6.751

Journal of Antimicrobial Chemotherapy, 2001, 48, 751-5.

Source: <https://exaly.com/paper-pdf/33272490/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
146	Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. 2002 , 6, 206-11		5
145	Discovery of 8-hydroxyadenines as a novel type of interferon inducer. 2002 , 45, 5419-22		70
144	Human herpesvirus 8, Kaposi's sarcoma, and associated conditions. 2002 , 22, 883-910		8
143	Anal condyloma and HIV-associated anal disease. 2002 , 82, 1199-211, vi		13
142	The future of vaccination as a treatment strategy in dermatological diseases. 2002 , 27, 608-13		1
141	Discovery of immunopotentiatory drugs: current and future strategies. 2002 , 130, 363-9		24
140	Die Zukunft von Impfungen als Therapiestrategie bei dermatologischen Erkrankungen. 2002 , 77, 685-690		
139	Novel agents and strategies to treat herpes simplex virus infections. 2003 , 12, 165-83		44
138	Imiquimod: modes of action. 2003 , 149 Suppl 66, 5-8		95
137	Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. 2003 , 28 Suppl 1, 27-9		9
136	Synthesis and biological evaluation of 2,8-disubstituted 9-benzyladenines: discovery of 8-mercaptoadenines as potent interferon-inducers. 2003 , 11, 2715-22		15
135	The imidazoquinolines and their place in the therapy of cutaneous disease. 2003 , 4, 1105-19		21
134	Developments in hepatitis C therapy during 2000-2002. <i>Expert Opinion on Emerging Drugs</i> , 2003 , 8, 9-25 3,7		6
133	The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. 2003 , 111, 380-8		84
132	Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. 2003 , 2, 205-17		53
131	Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. 2003 , 171, 3977-82		239
130	Imiquimod. 2003 , 16, 85-9		69

129	Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection. 2003 , 11, 81-7	1
128	New and emerging vaccination strategies for prevention and treatment of dermatological diseases. 2004 , 3, 421-31	3
127	Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. 2004 , 39, 554-67	51
126	Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. 2004 , 22, 1799-809	80
125	Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. 2004 , 114, 174-82	284
124	New adjuvants for parenteral and mucosal vaccines. 2005 , 60, 235-41	14
123	Microglia activation in rat spinal cord by systemic injection of TLR3 and TLR7/8 agonists. 2005 , 164, 154-60	36
122	Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism. 2005 , 49, 3546-9	27
121	Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. 2005 , 175, 1551-7	334
120	Host cell targets in HCV therapy: novel strategy or proven practice?. 2005 , 16, 69-90	9
119	Current use of anti-infectives in dermatology. 2005 , 3, 557-91	2
118	Toll-like receptors and airway disease. 2006 , 3, 317-324	
117	Topical treatment of nasal keratoacanthoma. 2006 , 117, 2516-7	3
116	Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. 2006 , 440, 233-6	891
115	New antiviral agents. 2006 , 73, 313-21	18
114	A tale of three Hs: HPV, HIV & HAART. 2006 , 2, 1-9	2
113	Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. 2006 , 177, 7959-67	210
112	The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. 2007 , 21, 1575-85	56

111	Incorporation of low molecular weight molecules into alpha(2)-macroglobulin by nucleophilic exchange. 2007 , 357, 433-8	5
110	Quinoline Analogs as Antiangiogenic Agents and Telomerase Inhibitors. 2007 , 213-229	12
109	TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. 2007 , 37, 2834-46	72
108	Imiquimod: mode of action. 2007 , 157 Suppl 2, 8-13	232
107	Emerging host cell targets for hepatitis C therapy. 2007 , 12, 209-17	23
106	Lack of colonic-inflammation-induced acute visceral hypersensitivity to colorectal distension in Na(v)1.9 knockout mice. 2008 , 12, 934-44	30
105	TLR7 and TLR8 as targets in cancer therapy. 2008 , 27, 190-9	224
104	Exploiting viral properties for the rational design of modern vaccines. 2008 , 7, 43-54	39
103	Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. 2008 , 233, 968-79	46
102	Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. 2008 , 112, 1750-8	137
101	Effect of tape stripping and adjuvants on immune response after intradermal DNA electroporation. 2009 , 26, 1745-51	16
100	Treatment of focal epithelial hyperplasia with topical imiquimod: report of three cases. 2009 , 26, 465-8	25
99	Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. 2009 , 49, 303-26	94
98	Small-molecule interferon inducers. Toward the comprehension of the molecular determinants through ligand-based approaches. 2009 , 49, 1777-86	8
97	Treatment of Classic Kaposi's Sarcoma with Topical Imiquimod. 2009 , 35, 147-149	9
96	Type I interferon in HIV treatment: from antiviral drug to therapeutic target. 2009 , 3, 269-282	4
95	Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model. 2010 , 130, 374-87	25
94	Mutations in classical swine fever virus NS4B affect virulence in swine. 2010 , 84, 1536-49	28

93	Vaccines in the management of hypertension. 2010 , 10, 1077-87		14
92	Toll-like receptors: role in dermatological disease. 2010 , 2010, 437246		66
91	Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. 2010 , 42, 268-354		186
90	Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with <i>Schistosoma mansoni</i> in mice. 2010 , 14, e781-7		30
89	Effect of imiquimod on partial-thickness burns. 2010 , 36, 97-108		15
88	Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle. 2011 , 652, 145-51		22
87	Modulation of $\gamma\delta$ cell responses by TLR ligands. 2011 , 68, 2357-70		93
86	Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 2389-93	2.9	25
85	The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. 2011 , 4, 275-89		115
84	Atlantic halibut experimentally infected with nodavirus shows increased levels of T-cell marker and IFN γ transcripts. 2012 , 37, 139-50		34
83	Antibacterial activities of Groebke-Blackburn-Bienaym β -derived imidazo[1,2-a]pyridin-3-amines. 2012 , 20, 5850-63		79
82	Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation. 2012 , 37, 620-5		19
81	Potential efficacy of imiquimod on immunity-related cytokines in murine skin in vivo and in human Langerhans cells in vitro. 2012 , 51, 1116-22		3
80	Characterisation and expression analysis of the Atlantic halibut (<i>Hippoglossus hippoglossus</i> L.) cytokines: IL-1 β , IL-6, IL-11, IL-12 β and IFN γ . 2012 , 39, 2201-13		66
79	Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis. 2013 , 10, 1045-55		62
78	Immunomodulatory effect of R848 on cytokine production associated with <i>Schistosoma mansoni</i> infection. 2013 , 112, 135-40		4
77	Delivery of host cell-directed therapeutics for intracellular pathogen clearance. 2013 , 11, 1225-35		16
76	Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis. 2013 , 30, 1349-61		26

75	Electrospun acetalated dextran scaffolds for temporal release of therapeutics. 2013 , 29, 7957-65		25
74	Imiquimod for anogenital warts in non-immunocompromised adults. 2013 ,		2
73	The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens. 2014 , 14, 1383-97		
72	Imiquimod for anogenital warts in non-immunocompromised adults. 2014 , CD010389		26
71	Phosphorylated ganciclovir derivatives: design, synthesis and in vitro and in vivo immunomodulatory activity. 2014 , 23, 2242-2251		9
70	Conjugation of a TLR7 agonist and antigen enhances protection in the <i>S. pneumoniae</i> murine infection model. 2014 , 87, 310-7		26
69	Liposomal resiquimod for the treatment of <i>Leishmania donovani</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 168-75	5.1	27
68	Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. 2014 , 37, 1234-40		47
67	Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. 2015 , 26, 1713-23		31
66	Administration of TLR7 agonist, resiquimod, in different types of chicken induces a mixed Th1 and Th2 response in the peripheral blood mononuclear cells. 2015 , 100, 105-8		13
65	Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells. 2015 , 194, 4215-21		45
64	Zoster Immunoglobulin-VF: A Potential Treatment for Molluscum Contagiosum in Immunosuppressed Children. 2015 , 32, e193		2
63	Differential Biological Activities of Swine Interferon- β Subtypes. 2015 , 35, 990-1002		16
62	Adjuvants: Classification, Modus Operandi, and Licensing. 2016 , 2016, 1459394		131
61	Toll-like receptors and cutaneous melanoma. 2016 , 12, 3655-3661		4
60	Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight. 2016 , 512, 147-157		25
59	In silico analysis of human Toll-like receptor 7 ligand binding domain. 2016 , 63, 441-50		7
58	Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line. <i>Journal of Dermatological Science</i> , 2016 , 81, 182-91	4.3	35

57	TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus. 2016 , 8, 327ra25		60
56	Synthesis and anti-cancer activity of 1,4-disubstituted imidazo[4,5-c]quinolines. 2016 , 14, 876-83		23
55	Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197. 2017 , 106, 2037-2045		18
54	Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken. 2018 , 119, 119-124		10
53	Toll-Like Receptor 7/8 Ligand, S28463, Suppresses Ascaris suum-induced Allergic Asthma in Nonhuman Primates. 2018 , 58, 55-65		4
52	3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine. 2018 , 106, 1587-1594		6
51	The Diagnostic and Therapeutic Challenge of Anal Intraepithelial Neoplasia. 2018 , 20, 38		1
50	Randomized clinical trial testing the efficacy and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of skin field cancerization: study protocol. 2018 , 18, 340		4
49	Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection. 2019 , 87,		2
48	Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and β Mannose as Adjuvants. 2019 , 30, 2811-2821		7
47	Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. 2019 , 18, 175-185		112
46	Resiquimod inhibits Newcastle disease virus replication by modulating host cytokines: An understanding towards its possible therapeutics. <i>Cytokine</i> , 2020 , 125, 154811	4	3
45	Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020 , 30, 126840	2.9	1
44	Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review. <i>Archives of Virology</i> , 2020 , 165, 263-284	2.6	8
43	Effect of Imiquimod on Tachyzoites of and Infected Macrophages and in BALB/c Mice. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 387	5.9	5
42	Effects of toll-like receptor-7 agonists on feeding behaviour, voluntary activity, cloacal temperature and crop emptying in chicks. <i>British Poultry Science</i> , 2020 , 61, 303-310	1.9	4
41	In Ovo Delivered Toll-Like Receptor 7 Ligand, Resiquimod Enhances Host Responses against Infectious Bronchitis Corona Virus (IBV) Infection. <i>Vaccines</i> , 2020 , 8,	5.3	3
40	An expeditious microwave assisted one-pot sequential route to pyrido fused imidazo[4,5-c]quinolines in green media. <i>New Journal of Chemistry</i> , 2021 , 45, 3280-3289	3.6	5

39	Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation. <i>Archiv Der Pharmazie</i> , 2021 , 354, e2000393	4.3	5
38	Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009099	4.8	14
37	Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice. <i>ACS Nano</i> , 2021 , 15, 4450-4466	16.7	21
36	In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 162, 105826	5.1	0
35	Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. <i>Advanced Drug Delivery Reviews</i> , 2021 , 175, 113803	18.5	13
34	Evaluation of Cellular Immune Responses in Dogs Immunized with Alum-Precipitated Autoclaved along with BCG and Imiquimod. <i>Iranian Journal of Parasitology</i> , 2021 , 16, 348-356	0.8	
33	Immunologic adjuvants. 2008 , 59-71		7
32	Imiquimod-induced ROS production disrupts the balance of mitochondrial dynamics and increases mitophagy in skin cancer cells. <i>Journal of Dermatological Science</i> , 2020 , 98, 152-162	4.3	16
31	Immunopathogenesis and therapy of cutaneous T cell lymphoma. <i>Journal of Clinical Investigation</i> , 2005 , 115, 798-812	15.9	200
30	Insights on the mechanism of action of immunostimulants in relation to their pharmacological potency. The effects of imidazoquinolines on TLR8. <i>PLoS ONE</i> , 2017 , 12, e0178846	3.7	5
29	Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy. <i>Oncotarget</i> , 2018 , 9, 13301-13312	3.3	18
28	Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016 , 20, v-vi, 1-486	4.4	34
27	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. <i>Indian Journal of Ophthalmology</i> , 2020 , 68, 693-702	1.6	53
26	Imiquimod: Kritische Wertung der möglichen Indikationen. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2003 , 140-147		
25	Therapeutic Strategies Targeting the Innate Antiviral Immune Response. 2008 , 223-251		
24	Type I Interferons and Receptors.		
23	Design and Development of Recombinant Vaccines with Viral Properties. 19-63		
22	Targeted and Personalized Therapy for Nonmelanoma Skin Cancers. 2015 , 29-46		

21	Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 1-2	3.7	0
20	Whole Cell Vaccines. 2007 , 275-295		
19	Cutaneous T-Cell Lymphoma. 2008 , 411-437		
18	Chemical reagents modulate nucleic acid-activated toll-like receptors.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 147, 112622	7.5	0
17	Discovery of new TLR7 agonists by a combination of statistical learning-based QSAR, virtual screening, and molecular dynamics. <i>Informatics in Medicine Unlocked</i> , 2021 , 27, 100787	5.3	
16	2-Aminopyridine - an unsung hero in drug discovery.. <i>Chemical Communications</i> , 2021 ,	5.8	3
15	The Impact of Prolonged Inflammation on Wound Healing.. <i>Biomedicines</i> , 2022 , 10,	4.8	3
14	Local skin reactions and the onset of influenza-like signs and symptoms induced by imiquimod.. <i>JAAD International</i> , 2022 , 7, 113-118	0.9	1
13	Herpes Simplex Viruses. <i>Methods and Principles in Medicinal Chemistry</i> , 2022 , 133-150	0.4	
12	Chitosan nanoparticles containing fusion protein (Hsp α -PPE44-Es α V) and resiquimod adjuvant (HPERC) as a novel booster vaccine for .. <i>Journal of Biomaterials Applications</i> , 2022 , 8853282221079105	2.9	1
11	Future Therapies for Hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 397-408	1.6	21
10	Topical and intralesional antiviral agents. 2013 , 473-480.e3		
9	New developments in the treatment of cutaneous leishmaniasis. <i>Asian Pacific Journal of Tropical Medicine</i> , 2022 , 15, 196	2.1	0
8	Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications. 2022 , 20,		0
7	Hepatocyte-targeted delivery of imiquimod reduces hepatitis B virus surface antigen. 2022 , 350, 630-641		0
6	Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments. 13,		0
5	In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents. 10,		0
4	Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity.		0

- 3 Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. **2023**, 15, 452
- 2 Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. **2023**,
- 1 Biomolecules Triggering Altered Food Intake during Pathogenic Challenge in Chicks. **2023**, 60, n/a